Bimekizumab for Hidradenitis Suppurativa: Pathophysiology and Promising Interventions

Hidradenitis suppurativa (HS) is a debilitating dermatologic disorder characterized by recurrent inflammation that affects the apocrine glands and hair follicles and profoundly impacts patients' quality of life. Current treatment strategies ranging from topical therapies to systemic biologics aim to alleviate symptoms and prevent disease progression. Bimekizumab, an IL-17A and IL-17F inhibitor, has emerged as a promising intervention in the HS treatment landscape. We present a comprehensive review of the underlying molecular pathophysiology of HS, current standards of care, and evaluation of the efficacy and safety of bimekizumab.